Objective To explore the clinical efficacy of continuous hyperthermic peritoneal perfusion chemotherapy (CHPPC) in the treatment of advanced cholangiocarcinoma and its long-term impact on survival time. Methods This was a retrospective study of 103 patients with advanced cholangiocarcinoma from Aug. 2014 to Jun. 2016 in Eastern Hepatobiliary Surgery Hospital of Second Military Medical University. The 46 patients in CHPPC group underwent CHPPC and 57 patients in control group received conventional intravenous chemotherapy. We recorded and analyzed the quality of life (KPS score), clinical efficacy, liver function indexes (including aspartate aminotransferase[AST], alanine aminotransferase[ALT], γ-glutamyl transferase[γ-GT], total bilirubin[TB] and alkaline phosphatase[ALP]), serum carbohydrate antigen 19-9 (CA19-9), adverse reaction and survival time of the patients in the two groups. Results The improvement rate of quality of life in the CHPPC group was significantly higher than that in the control group (34.78%[16/46] vs 19.30%[11/57], P<0.05). The effective rate of the CHPPC group was significantly higher than that of the control group (67.39%[31/46] vs 40.35%[23/57], P<0.01). The median levels of AST, ALT, γ-GT, TB, ALP and CA19-9 in the CHPPC group were significantly lower than those in the control group (P<0.05). The incidences of aleucocytosis, thrombocytopenia and liver function injury in the CHPPC group were significantly lower than those in the control group (P<0.05), and there was no significant difference between two groups in the incidence of reduction of hemoglobin, gastrointestinal adverse reaction or renal injury (P>0.05). The survival time of the patients in the CHPPC group was significantly higher than that in the control group ([12.00±2.47] months vs[6.00±0.80] months, P<0.01). Conclusion CHPPC shows a significant clinical efficacy in the treatment of advanced cholangiocarcinoma. It can effectively decrease the median level of serum CA19-9, improve the liver function and quality of life,and prolong the survival time of the patients.